KZKunpeng Zhang

Kunpeng Zhang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kunpeng Zhang has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Baodong Ye

    Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)

    1 shared publication
  • Dijiong Wu

    Department of Hematology, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, P.R. China

    1 shared publication
  • Jingjing Liu

    School of Life Science and Technology, The Key Laboratory of Developmental Genes and Human Disease, Southeast University

    1 shared publication
  • Qi Liu

    The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)

    1 shared publication
  • Shun He

    School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China, zcmu.edu.cn

    1 shared publication
  • Xinru Jia

    The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)

    1 shared publication

Latest Publications

  • Open Access

    Myeloid‐Derived Suppressor Cells: Immunoregulatory Roles and Therapeutic Prospects in Immune‐Mediated Hematological Disorders

    by Qi Liu, Kunpeng Zhang, Shun He, Xinru Jia, Jingjing Liu, Dijiong Wu, Baodong Ye

    Myeloid‐derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that have been increasingly defined and characterized over the past two decades, known for their remarkable capacity to expand and exert immunosuppressive effects in various pathological contexts, such as malignancies, infections, and inflammatory diseases. Although MDSCs have attracted significant attention in tumor immunology, their multifaceted roles in immune‐mediated hematological disorders remain comparatively understudied and less understood, especially in contrast to their well‐documented functions in both solid and hematological malignancies. This review delves into the biological characteristics and functional mechanisms of MDSCs, as well as their dual immunomodulatory roles in various immune‐mediated hematological disorders such as immune thrombocytopenia and aplastic anemia. Substantial evidence indicates that in these diseases, the expansion, recruitment, and function of MDSCs are significantly altered, with their levels closely correlated to disease activity. Based on these findings, we further explore the therapeutic potential of targeting MDSCs. Manipulating MDSCs offers a pioneering perspective for the development of next‐generation immunotherapies, which holds promise for reshaping the current treatment landscape of immune‐mediated hematological disorders.